If BP cared about NWBO, it would have been bought. Instead none of them care. Even Merck, who has full access to UCLA/SPORE trial data for ATL (not DCVax-L) took a pass a bought another GBM biotech company.
Oct 2024, Merck bought Modifi Biosciences for their GBM/DNA modification drug (KL-50) for $1.3 billion.
Most of the active GBM trials are small early stage biotechs. Only a a couple of BP - Novartis, AZ. Limited spending in GBM -- look it up.
Rest of you post demonstrates real lack of knowledge of pharmaceuticals.
Market Data 
Markets 
AI
